{"id":147479,"date":"2025-04-17T11:43:06","date_gmt":"2025-04-17T06:13:06","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=147479"},"modified":"2025-04-17T11:43:09","modified_gmt":"2025-04-17T06:13:09","slug":"pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/","title":{"rendered":"Pharma stock skyrockets 13% after receiving USFDA approval for Qualified Infectious Disease Product"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-782280473\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>The shares of the Pharmaceuticals company, specializing in developing and manufacturing critical care injectable pharmaceuticals, jumped upto 13 percent after receiving US FDA approval for Qualified Infectious Disease Product (QIDP) designation for its novel drug formulation VRP-034.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-2218812563\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Price action<\/strong><\/h2><p>With a market capitalization of Rs. 161.10 Crores on Thursday, the shares of <strong><a href=\"https:\/\/portal.tradebrains.in\/stocks\/VENUSREM\" target=\"_blank\" rel=\"noreferrer noopener\">Venus Remedies Limited<\/a><\/strong> jumped upto 13.6 percent, making a high of Rs. 354.00 compared to its previous closing price of Rs. 311.60.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>What Happened&nbsp;<\/strong><\/h2><p>Venus Remedies specializes in developing and manufacturing critical care injectable pharmaceuticals, has received the US FDA\u2019s approval for Qualified Infectious Disease Product (QIDP) designation for its novel drug formulation VRP-034, a next-generation polymyxin B sulphate designed to treat bloodstream infections while significantly reducing kidney toxicity.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Key preclinical\u00a0 findings for VRP-034 include:<\/strong><\/h2><ul class=\"wp-block-list\"><li>Up to 70 percent reduction in nephrotoxicity compared to the marketed PMB<\/li>\n\n<li>Robust efficacy against resistant pathogens in both in vitro and animal models<\/li>\n\n<li>Favorable safety profiles across multiple toxicity studies using advanced rental biomarkers and human organ-on-a-chip models<\/li><\/ul><h2 class=\"wp-block-heading has-medium-font-size\"><strong>About the Company<\/strong><\/h2><p>\u200bVenus Remedies Limited is a research-driven pharmaceutical company headquartered in Panchkula, India. Established in 1989, it specializes in manufacturing super-specialty injectable formulations in critical care segments such as oncology, anti-infectives, neurology, and pain management. The company operates in over 80 countries, with exports contributing to more than 70 percent of its revenue.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-3077257801\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Key Insights&nbsp;<\/strong><\/h2><p>The company\u2019s P\/E ratio of 14.94 is well below the industry average of 53.03, suggesting it may be undervalued. It has a low debt-to-equity ratio of 0.08, indicating strong financial health.&nbsp;<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Financials&nbsp;<\/strong><\/h2><p>The company&#8217;s revenue rose by 22.7 percent from Rs. 145.77 crore to Rs. 178.89 crore in Q3FY24-25. Meanwhile, Net profit rose from Rs. 6.85 crores to Rs. 19.6 crores during the same period.<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by Sridhar J&nbsp;<\/strong><\/p><\/blockquote><p class=\"has-medium-font-size\"><strong>Disclaimer<\/strong><\/p><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing<\/strong>.<\/p><div class=\"trade-after-content\" id=\"trade-1736956553\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>The shares of the Pharmaceuticals company, specializing in developing and manufacturing critical care injectable pharmaceuticals, jumped upto 13 percent after receiving US FDA approval for Qualified Infectious Disease Product (QIDP) designation for its novel drug formulation VRP-034. Price action With a market capitalization of Rs. 161.10 Crores on Thursday, the shares of Venus Remedies Limited [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":125304,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[6616,948,936,2597,27199,19485,9806,25201],"class_list":["post-147479","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-pharma-stock","tag-stock-market","tag-stock-market-news","tag-stocks-to-watch","tag-usfda","tag-venus-remedies","tag-venus-remedies-latest-news","tag-venus-remedies-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock skyrockets 13% after receiving USFDA approval for Qualified Infectious Disease Product - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"The shares of the Pharmaceuticals company, specializing in developing and manufacturing critical care injectable pharmaceuticals, jumped upto 13 percent after receiving US FDA approval for Qualified Infectious Disease Product (QIDP) designation for its novel drug formulation VRP-034.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock skyrockets 13% after receiving USFDA approval for Qualified Infectious Disease Product\" \/>\n<meta property=\"og:description\" content=\"The shares of the Pharmaceuticals company, specializing in developing and manufacturing critical care injectable pharmaceuticals, jumped upto 13 percent after receiving US FDA approval for Qualified Infectious Disease Product (QIDP) designation for its novel drug formulation VRP-034.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-17T06:13:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-17T06:13:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/\",\"name\":\"Pharma stock skyrockets 13% after receiving USFDA approval for Qualified Infectious Disease Product - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"datePublished\":\"2025-04-17T06:13:06+00:00\",\"dateModified\":\"2025-04-17T06:13:09+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"The shares of the Pharmaceuticals company, specializing in developing and manufacturing critical care injectable pharmaceuticals, jumped upto 13 percent after receiving US FDA approval for Qualified Infectious Disease Product (QIDP) designation for its novel drug formulation VRP-034.\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock skyrockets 13% after receiving USFDA approval for Qualified Infectious Disease Product\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock skyrockets 13% after receiving USFDA approval for Qualified Infectious Disease Product - Trade Brains Features","description":"The shares of the Pharmaceuticals company, specializing in developing and manufacturing critical care injectable pharmaceuticals, jumped upto 13 percent after receiving US FDA approval for Qualified Infectious Disease Product (QIDP) designation for its novel drug formulation VRP-034.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock skyrockets 13% after receiving USFDA approval for Qualified Infectious Disease Product","og_description":"The shares of the Pharmaceuticals company, specializing in developing and manufacturing critical care injectable pharmaceuticals, jumped upto 13 percent after receiving US FDA approval for Qualified Infectious Disease Product (QIDP) designation for its novel drug formulation VRP-034.","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2025-04-17T06:13:06+00:00","article_modified_time":"2025-04-17T06:13:09+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/","name":"Pharma stock skyrockets 13% after receiving USFDA approval for Qualified Infectious Disease Product - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","datePublished":"2025-04-17T06:13:06+00:00","dateModified":"2025-04-17T06:13:09+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"The shares of the Pharmaceuticals company, specializing in developing and manufacturing critical care injectable pharmaceuticals, jumped upto 13 percent after receiving US FDA approval for Qualified Infectious Disease Product (QIDP) designation for its novel drug formulation VRP-034.","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-skyrockets-13-after-receiving-usfda-approval-for-qualified-infectious-disease-product\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock skyrockets 13% after receiving USFDA approval for Qualified Infectious Disease Product"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/147479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=147479"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/147479\/revisions"}],"predecessor-version":[{"id":147480,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/147479\/revisions\/147480"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/125304"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=147479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=147479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=147479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}